First Trust Advisors LP increased its holdings in Glaukos Corporation (NYSE: GKOS) by 2,085.8% in th

GKOS' Q2 loss narrows as revenues jump 50% on iDose TR and Epioxa growth, lifting its 2026 sales out

Glaukos NYSE: GKOS reported record second-quarter 2026 consolidated net sales of $185.6 million, up

Although the revenue and EPS for Glaukos (GKOS) give a sense of how its business performed in the qu

Glaukos Corporation (GKOS) Q2 2026 Earnings Call Transcript

Glaukos (GKOS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical

Glaukos Corporation remains rated "Hold" as shares approach technical resistance near $160 ahead of

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical

Bank of New York Mellon Corp reduced its stake in shares of Glaukos Corporation (NYSE: GKOS) by 3.6%

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Stifel analyst Tom Stephan maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target f

Truist Securities analyst Richard Newitter maintains Glaukos (NYSE:GKOS) with a Buy and raises th

Alex R. Thurman generated ~$1.6 million in gross proceeds by selling 10,000 shares at $155 per share

Abbott Laboratories offers a highly diversified healthcare portfolio with strong profitability acros

GKOS has surged nearly 45% since May-end as upbeat iDose TR commentary, strong sales and growth expe

This medical stock is in the buy zone of a base. The glaucoma treatment developer raised its revenue

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical

Pre-Market Stock Futures: Futures are trading mixed as we get ready to start the first full week of

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical

Top Wall Street analysts changed outlook on top names. Baird raised prices for Ryder System and J

Glaukos is riding strong on iDose TR growth and launching Epioxa into a large underpenetrated market

Wall Street analysts change outlook on top stocks. For full list of changes including upgrades/downg

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical

GKOS beats Q1 estimates with 41% revenue growth, narrows loss and raises 2026 outlook as glaucoma an

US stocks mixed, Dow up 400 pts. Caterpillar, Bandwidth, Everspin, Vistance, IMPINJ, Novocure, Viavi

Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly ear

Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1

Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (NYSE:EDV) is estimat

Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its

Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for i

  Companies Reporting Before The Bell • Fresh Del Monte Produce (NYSE:FDP) is likely to report qua

  Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report qu